How much will lorlatinib cost in 2024?

Lorlatinib is a third-generation tyrosine kinase inhibitor (TKI) that specifically targets ALK (anaplastic lymphoma kinase) and Non-small cell lung cancer (NSCLC) with positive mutations in ROS1(C-rosproto-oncogene1). It blocks the proliferation and metastasis of tumor cells by inhibiting the activity of ALK and ROS1 genes, and effectively responds to mutations that cause resistance to previous-generation drugs. The particularly outstanding advantage of lorlatinib is its good blood-brain barrier penetration ability, which can significantly control and alleviate brain metastases and improve patients' survival rate and quality of life.

Larlatinib has been launched in China and has been included in the medical insurance catalog. Patients can purchase it through formal channels in China. However, even with medical insurance reimbursement, out-of-pocket expenses are still high, with monthly costs of about 10,000 to 20,000 yuan. The specific reimbursement ratio and actual price may vary due to different regional policies. It is recommended that patients directly consult the local hospital or medical insurance department to obtain accurate information.

In foreign markets, the price difference of lorlatinib is obvious. The price of original drugs in Türkiye is relatively cheap, about more than 7,000 yuan per month; the price of original drugs in Hong Kong is relatively high, up to about 30,000 yuan. In contrast, generic drugs produced in Laos and Bangladesh have become the choice of many patients because of their low prices, which usually range from more than 1,000 yuan to several thousand yuan. These generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, but there may be certain differences in production and quality control standards. You need to be careful to choose formal channels when purchasing.

Patients should strictly follow the doctor's instructions before taking medication and determine a suitable treatment plan based on the individual mutation type and condition. At the same time, attention should be paid to the formality of drug sources to avoid using drugs of substandard quality that may affect efficacy or cause adverse reactions. The emergence of lorlatinib provides new treatment hope for patients with ALK and ROS1 positive lung cancer, and has also become an important breakthrough in the treatment of advanced lung cancer.

xa0

References:

China National Medical Products Administration: https://www.nmpa.gov.cn/